Tulane University Receives Funding for T-prop Treatment

Researchers in New Orleans secured a $4 million federal contract to develop an immune-boosting infection treatment.

Updated on Oct. 27, 2026 in Life Sciences

Tulane University Receives Funding for T-prop Treatment

Live Poll

Do you support prioritizing the development of rapid, temporary immune treatments over traditional long-term vaccines?

Tulane University has been awarded a $4 million contract from the U.S. Department of Defense's Defense Threat Reduction Agency to develop a novel treatment known as T-prop. This four-year project aims to create a rapid defense against infectious threats by activating the body's innate immune system.

Why it matters

The development of T-prop aims to provide military personnel with rapid protection against a wide range of viruses and bacteria. By utilizing bacterial outer membrane vesicles to trigger the immune system, the project seeks to establish a versatile defense mechanism.

In a preclinical mouse study, T-prop provided full protection against influenza exposure when administered 24 hours prior. Researchers are currently evaluating the efficacy of the treatment at multiple delivery intervals and methods.

The players

Tulane University

A private research university in New Orleans that hosts the laboratory developing the T-prop treatment.

Defense Threat Reduction Agency

A combat support agency within the United States Department of Defense focused on countering weapons of mass destruction and infectious threats.

The details

The treatment works by using outer membrane vesicles derived from bacteria to stimulate the innate immune system. Researchers plan to investigate various delivery methods, including nasal sprays and oral tablets, to ensure rapid and effective administration.

Tulane University received the $4 million contract on October 27, 2026.
The federal research project is scheduled to last for 4 years.

The Big Picture

This project aligns with the Defense Threat Reduction Agency's infectious disease research portfolio by prioritizing the development of medical countermeasures for military readiness. The grant extends the agency's efforts by funding new, innate immune-activating platforms.

While currently in the research phase, this technology could eventually lead to new oral or nasal treatments that offer rapid protection against seasonal and emerging infections. Successful human trials could transform how medical professionals provide preventative care for infectious outbreaks.

The takeaway

The development of treatments that stimulate the innate immune system represents a strategic shift toward broad-spectrum infection prevention. Readers should look for future updates as the four-year development timeline progresses from animal studies to human clinical trials.